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ABSTRACT 
This study aimed at evaluating the correlation between changes in Hemoglobin A1c (HbA1c) and fasting serum lipids, and 
Central Macular Thickness (CMT) in patients with Non-Proliferative Diabetic Retinopathy (NPDR). 
In the current research, both eyes of 68 patients with mild or moderate NPDR, without clinically significant macular 
edema, were studied. Levels of fasting serum lipids, HbAlc, and CMT were measured during the first visit and at the end 
of the follow-up period (3 months). For statistical analysis, CMTs of each eye were studied and the correlation of changes 
was investigated. Additionally, the direction of changes in CMT for each eye was determined, and whether the changes 
in both eyes were symmetrical was investigated. 
Out of 68 patients, 24 were male and 44 were female. The mean CMT of all eyes was 290.05 ± 48.90 µm during the first 
visit and 286.80 ± 37.57 µm on the 3rd month follow-up. The mean HbAlc was 8.71 ± 1.82% at first visit to the hospital 
and the mean HbAlc was 8.39 ± 1.65% at the final visit. Although the changes in HbA1c and CMT during the follow-up 
period were statistically insignificant, the correlation of these 2 values was statistically significant (p=0.01). However, 
amongst l3 patients, the CMTs were asymmetrically changed in each eye during the follow-up period.  
To the best of the author’s knowledge, this was the first study, which indicated a significant correlation in changes of 
CMT and HbA1c, even amongst patients with low-grade diabetic retinopathy. Demonstration of asymmetric changes in 
CMT of each treatment-naive eye of the same patient, during changes in systemic conditions, was another important 
finding of this study. 
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INTRODUCTION
Diabetes Mellitus (DM) is a chronic metabolic syndrome 
characterized by hyperglycemia due to insulin resistance. 
Long-standing DM influences many organs and tissues, 
leading to several complications, such as Diabetic 
Retinopathy (DR) and Diabetic Macular Edema (DME) [1, 
2]. The pathogenesis of DME remains unclear as complex 
processes, with various contributing factors, seem to be 
involved. Increasing diabetes duration with chronic 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2018; 7(1)  
 
11 BIOCHEMICAL PARAMETERS AND CENTRAL MACULAR THICKNESS 
hyperglycemia, advanced glycation end-products, such as 
levels of glycosylated hemoglobin (HbA1c), free oxygen 
radicals, protein kinase C, hypercholesterolemia, and 
blood pressure play important roles in such progressive 
metabolic diseases [3-5]. Hemoglobin A1c is the index of 
average glycemic control over the previous 2 to 3 months 
and indicates the level of diabetic control; therefore, 
increased HbA1c concentration is the most important 
risk factor for the development of DM complications, 
mainly DME [6]. Several conflicting reports regarding the 
effect of serum lipid profile on macular edema have been 
published, a number of which did not show any statistical 
correlation between serum lipid parameters and CMT, 
while others showed that high serum lipid levels indicate 
a risk of hard exudate and macular edema development 
[3-6]. The purpose of the current study was to evaluate 
and compare the correlation between changes in HbA1c, 
fasting serum lipids, and Central Macular Thickness 
(CMT) in patients with low-grade DR. Additionally, the 
researchers aimed at examining whether the changes in 
CMT of each eye were symmetrical under the changing 
systemic conditions of the same subject. 
MATERIALS AND METHODS 
The current study was carried out at the Ulucanlar Eye 
Education and Research Hospital. All procedures were 
designed in accordance with ethical standards and 
principles of the Declaration of Helsinki for human 
subjects. The Medical Ethics Committee of Diskapi 
Training and Research Hospital reviewed and approved 
the study protocol and informed consent forms were 
obtained from all participants. Both eyes of 68 patients 
with type 2 DM and mild or moderate Non-Proliferative 
DR (NPDR) and without Clinical Significant Macular 
Edema (CSME), according to the criteria of the 
International Clinical Diabetic Retinopathy Disease 
Severity Scale [7] and Early Treatment Diabetic 
Retinopathy Study (ETDRS), were studied in the current 
research [8]. The presence of type 2 DM in each patient 
was confirmed by an internal medicine consultant. For 
systemic evaluation, presence of other systemic diseases 
associated with type 2 DM, including hypertension, 
diabetic nephropathy, and diabetic neuropathy, and 
types of diabetic treatment and history of other 
medications, such as antihypertensive, were recorded for 
each patient. Patients with a history of other retinal 
diseases, glaucoma, uveitis, ocular trauma, and any type 
of ocular surgery, eyes with proliferative DR, laser 
photocoagulation or intravitreal injections were excluded 
from the current study. All patients had undergone 
detailed ophthalmic evaluation including Visual Acuity 
(VA) and intraocular pressure measurement, detailed slit 
lamp, and dilated fundus examinations. All 
measurements and evaluations were performed on the 
patients’ first visit and at the 3
rd
 month follow-up.  None 
of the patients had ocular risk factors, such as cataract 
extraction, trauma, inflammation, and topical treatment, 
which may affect CMT during this period. To evaluate the 
correlation between changes in biochemical parameters, 
including fasting serum lipids, levels of High-Density 
Lipoprotein (HDL), Low-Density Lipoprotein (LDL), 
Triglyceride (TG), and plasma HbA1c were recorded for 
each subject through peripheral blood sampling. Samples 
were evaluated with standard methods, including a 
Roche Modular-P 800 device (Roche Diagnostic, GmbH, 
Germany) for fasting serum lipids. Low-Density 
Lipoprotein levels were calculated with available lipid 
data, using the Friedewald formula. Hemoglobin A1c was 
measured by high-performance liquid chromatography-
ultraviolet detection [9]. 
Central Macular Thickness was measured on the same 
day of serum parameters evaluation. Spectral Domain 
Optical Coherence Tomography (SD-OCT) (Spectralis; 
Heidelberg Engineering, Heidelberg, Germany), volume 
scans of 20x20 degree, consisting of 49 horizontal high-
resolution line sections and including scanning laser 
ophthalmoscopy en face and fundus auto-fluorescence 
images of the macula were obtained with HRA2 
(Heidelberg Retina Angiograph-Optical Coherence 
Tomography, Heidelberg Engineering, Heidelberg, 
Germany). The morphology of central retinas, such as 
macular cystic changes or diffuse macular thickening, 
was evaluated by the same observer. Central Macular 
Thickness was measured from the same area each time 
with the aid of an eye tracker system, and to obtain high 
quality images without pupil dilation, motion artifacts 
were eliminated by the SD-OCT device. To evaluate 
changes in CMT during the follow-up period, differences 
in macular thickness in the same location of the fovea 
were calculated with the progression mode of the SD-
OCT devices, during each observation period. The 
direction of CMT changes for each eye was determined 
by different analysis systems in OCT. Statistical analyses 
of data were performed using the Statistical Package for 
the Social Sciences software (SPSS Inc., Chicago, IL, USA), 
version 24. The normality of variables was assessed by 
the Kolmogorov-Smirnov test and the variables were 
evaluated with statistical methods. The Wilcoxon test 
was used for comparison of each parameter, measured 
during different examination periods, as variables did not 
have a normal distribution. In order to evaluate the 
correlations between non-normally distributed variables, 
the correlation coefficients and their significance were 
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calculated using the Spearman's correlation test. Mann-
Whitney U test was used to evaluate the significance of 
correlations between non-normally distributed numerical 
variables of different groups. To evaluate the correlation 
between changes of HbAlc, the CMT chi-square test was 
performed. The P values of < 0.05 were considered 
significant. 
RESULTS 
Amongst 68 patients, 24 (35.30%) were male and 44 
(64.70%) were female. The number of female subjects 
was significantly more than male subjects (P = 0.03). The 
mean age was 57.5 years (range of 38 to 80 years). The 
mean age in the female group was 60 years (range of 39 
to 74 years), while it was 53 years (range of 38 to 80 
years) in male patients. The difference was statistically 
insignificant (P = 0.10). Hypertension was observed in 28 
(41.2%) out of 68 cases, being the most frequent 
systemic disease associated with DM in the current 
study. There was also no significant difference between 
genders regarding the presence of hypertension 
(p=0.14). Any other complications of DM, such as 
polyneuropathy, nephropathy, history of dialyses, 
diabetic foot or any other systemic disease, were not 
present in any of the patients. A total of 43 patients were 
under insulin treatment, while 23 were receiving oral 
anti-diabetic medication, 1 patient was under combined 
treatment of oral anti-diabetic medications and insulin 
injection, and only 1 patient did not require any systemic 
treatment for DM. The summary of demographic data, 
presence of hypertension, and treatment protocol of 
diabetes mellitus, according to gender, is presented in 
Table 1. 
The mean HbAlc was 8.71 ± 1.82% when the patients 
were first presented to the hospital, while it changed to 
8.39 ± 1.65% on the 3rd month follow-up. The mean 
HbAlc was significantly higher than the recommended 
upper limits of patients with diabetes, according to the 
American Diabetes Association (ADA) recommendations 
[10]. In 22 patients, the HbA1c level was increased, while 
it was decreased in 39 patients, and in only 7 subjects, 
the HbA1c level remained the same.  Both during the 
initial visit and on the 3
rd
 month, HbA1c levels were 
normally distributed, as evaluated by the Kolmogrov-
Smirnov test, and there was an insignificant decrease 
during the 3rd month follow-up visit (P = 0.06). 
Furthermore, the difference between fasting serum lipid 
measurements was not statistically significant (p values 
were 0.25, 0.62, and 0.09 when comparing HDL, LDL, and 
TG levels, respectively). All of these serum parameters 
were also normally distributed during each period. When 
the patients were first presented, the mean CMT of all 
eye examinations was 290.05 ± 48.90 µm, while it 
became 286.80 ± 37.57 µm on the 3rd month follow-up. 
The difference between CMT during the 2 observation 
periods was statistically insignificant (P = 0.11), although 
a slight decrease was observed on the 3rd month follow-
up visit. In contrast to serum parameters, CMTs were not 
normally distributed during both observation periods. 
The mean value ± Standard Deviation (SD) of HbA1c, 
serum lipids, and CMT during the first and final visit are 
presented in Table 2. 
 
Table 1. Summary of Demographic Data, Presence of 
Hypertension, and Treatment Protocol of Patients with 
Diabetes Mellitus According to Gender 
Variables Male Female P value* 
Demographic data    
Sample size, n 24 44 0.027 
Mean age, Y 53 60 0.103 
Hypertension, n 7 21 0.137 
Treatment protocol    
Insulin, n 13 30 0.316 
Oral anti-diabetic 
medication, n 
10 13 0.628 
Insulin + Oral anti-diabetic 
medication, n 
0 1  
n = number; Y = years. *P Value for all Treatment Groups 
according to the MANN-Whitney U Test. 
 
A total of 41 patients out of 68 patients had parallel 
changes in HbAlc and CMT. Both the HbAlc and CMT 
were increased in 16 patients, and in 25 patients, they 
decreased during the follow-up period. On the other 
hand, in 20 (29.41%) patients, HbAlc changes were 
discorrelated with CMTs, in which 14 patients’ HbAlc 
levels were decreased while the CMTs were increased, 
and in 6 patients HbA1c were increased while the CMTs 
were decreased. The overall changes in HbA1c and CMT 
during the follow-up period were significantly correlated, 
according to Yates continuity correction of chi-square 
test (P = 0.01). However, none of the serum lipid changes 
were correlated with the CMT changes (P values were 
0.09, 0.15, and 0.70 when comparing HDL, LDL, and TG, 
respectively). Analyses of the correlation of differences in 
CMT with HbA1c, HDL, LDL, and TG are provided in Table 
3. 
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Table 2. The Mean Value ± Standard Deviation of Hemoglobin A1c, Serum Lipids, and Central Macular Thickness During the First and Final 
Visit 
Variables First visit Last visit P value* 
Hemoglobin A1c (%) 8.71 ± 1.8 8.39 ± 1.6 0.062 
Serum lipids    
HDL (mmol/L) 48.3 ± 11.8 49.5 ± 15.9 0.254 
LDL (mmol/L) 119.1 ± 44.4 118.6 ± 54.7 0.623 
TG (mmol/L) 165.3 ± 89 159.5 ± 94 0.094 
CMT (µm) 290.5 ± 48.90 286.8 ± 37.57 0.107 
HDL = High-Density Lipoprotein; LDL = Low-Density Lipoprotein; TG = Triglyceride; CMT = Central Macular Thickness; % = Percentage; 
mmol/L = Millimoles per Litre; µm = Micrometer; SD = Standard Deviation. *P Value for all Treatment Groups according to Wilcoxon Test. 
 
Table 3. Analyses of the Correlation of Differences in Central Macular Thickness with Hemoglobin A1c, High-Density Lipoprotein, Low-
Density Lipoprotein, and Triglyceride 
Variables Central macular thickness P value* 
 Increased (n) Decreased (n)  
Hemoglobin A1c   0.013 
Increased (n) 6 (27.3 %) 16 (72.7 %)  
Decreased (n) 25 (64.1 %) 14 (35.9 %)  
High-density lipoprotein   0.092 
Increased (n)  20 (64.5 %) 11 (35.5 %)  
Decreased (n) 10 (38.5 %) 16 (61.5 %)  
Low-density lipoprotein   0.154 
Increased (n) 12 (41.4 %) 17 (58.6%)  
Decreased (n) 19 (63.3 %) 11 (36.7 %)  
Triglyceride   0.701 
Increased (n) 13 (46.4 %) 15 (53.6 %)  
Decreased (n) 18 (54.5 %) 15 (45.5 %)  
CMT = Central Macular Thickness; HbA1c = Hemoglobin A1c; HDL = High-Density Lipoprotein; LDL = Low-Density Lipoprotein; 
TG=Triglyceride; n = Number; % = Percentage.*P Value for all Treatment Groups according to Chi-Square Test. 
 
A total of 55 subjects (80.88%) had CMT changes, which 
had the same direction in both eyes of the same patient. 
In 28 subjects, CMTs of both eyes were decreased while 
it was increased in both eyes of 27 subjects. During the 
follow-up period, in 13 subjects (19.11%), CMTs were 
asymmetrically changed, amongst which in 3 subjects 
CMTs were increased in one eye while it remained the 
same in the other eye. Similarly, in 3 subjects, CMT was 
decreased in one eye while its level did not change on 
the other side, and in 7 subjects, CMT was increased in 
one eye while it was decreased in the other eye. 
DISCUSSION 
In the current study, a correlation was found between 
macular thickness and both HbA1c and fasting serum 
lipids, as an indirect evidence of metabolic control. Type 
2 DM is a complex disease and the risk of developing DR 
was found to be associated with several factors, such as 
diabetes duration, cardiovascular disease, and blood 
pressure [2, 5, 6]. Thapa et al. [6] found that concurrent 
hypertension was observed in 55.76% and abnormal lipid 
profile in 52.56% of their subjects. In the current study, 
results similar to that of Thapa et al. [6] were found. In 
the mentioned study, hypertension was observed in 
58.82% of patients, being the most frequent systemic-
associated factor in patients with diabetes. In clinical 
practice, decision to initiate treatment is based on retinal 
findings in biomicroscopy and SD-OCT changes rather 
than VA. The findings of Pieramici et al. [11] reaffirm the 
discordance between retinal thickness and VA, which had 
been widely accepted and demonstrated previously. In 
accordance with previous studies, the current evaluation 
also focused on the anatomic correlation with both 
fasting blood lipids and HbAlc rather than VA. Thapa et 
al. [6] observed that poor glycemic control (HbA1c > 7%) 
was found in 73.97% of newly diagnosed proliferative DR 
among patients with type 2 DM. Even though the current 
study only evaluated NPDR, high HbA1c (HbA1c > 7%) 
was seen in 79.4% of the subjects during both visits, 
which was very similar to the results of Thapa et al. This 
finding indicates that uncontrolled blood sugar is very 
common in patients with DR of any stage. According to 
several studies, reduction of HbAlc values decreases the 
risk of development or progression of any stage of DR 
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among patients with type 2 DM [6, 12-14]. In addition, 
Benarous et al. [13] reported that HbA1c had a positive 
correlation with DR stage, which was 7.3% in patient 
without DR, 8.0% in eyes with DR, 8.1% in eyes with 
DME, and increased up to 8.3% in eyes with CSME. 
Various studies have indicated that a higher HbA1c level 
is associated with the occurrence of DME [14, 15]. Jew et 
al. [5] published his work on the correlation between 
HbA1c and DME, in which the HbA1c was 7.8% in eyes 
without DME while it was 10.3% in eyes with DME. Such 
studies suggest a significant correlation between HbA1c 
and different stages of DR, yet the range of systemic and 
local conditions between mild NPDR and severe 
proliferative DR is very large. Additionally, DME is an 
important outcome and can occur at any stage of DR, 
being a major cause of visual impairment and blindness. 
Several SD-OCT images on DME, such as diffuse retinal 
thickening, serous retinal detachment, tractional retinal 
detachment due to posterior hyaloid traction, and 
cystoid macular edema, have been described, with all of 
these patterns generally co-existing with one another 
[16-18]. To evaluate the real effect of systemic factors on 
CMT and exclude local factors, the current study did not 
include patients with vitreomacular/vitreopapillary 
traction. To enhance homogeneity and validity of the 
study group, only the treatment-naive eyes with mild and 
moderate NPDR, which did not need laser 
photocoagulation or intravitreal anti-Vascular Endothelial 
Growth Factor (anti-VEGF) injection, were evaluated. 
In the current study, the mean HbA1c was 8.71% and 
CMT was 290.05 µm at initial visit, while the mean HbA1c 
was decreased to 8.39% and CMT was decreased to 
286.8 µm in eyes with NPDR. A total of 60.29% of 
patients had parallel changes in HbA1c and CMT, which 
was statistically correlated.  Ozturk et al. [19] found 
similar results, where the serum HbAlc values were found 
to correlate with change in CMT during the anti-VGF 
treatment. The mean HbAlc was 8.25 ± 1.74% (range of 
5.7% to 12.7%) in their sample, which was very similar to 
that of the current study, while the mean CMT was 468 
µm (range of 255 to 964 µm) in their study, which was 
higher than the current subjects. This may be because 
patients with advanced DR, who needed anti-VGF 
treatment, were enrolled in their study. Suwal et al. [2] 
showed that each of the serum lipid associations with 
DME were not statistically significant and serum lipid 
profiles, including total cholesterol, HDL, LDL, and TG, 
had no effect on CMT.  Similarly, Benarous et al. [13], 
found that serum lipid levels were not correlated with 
the development of DME or increased macular thickness. 
On the other hand, Sasaki et al. (20) observed that total 
cholesterol, HDL, and TG levels were not significantly 
associated with CMT; however, LDL was positively 
associated with CMT. The current study did not evaluate 
subjects with DME and each of the subjects had low-
grade DR compared with the studies of Suwal et al. [2] 
and Benarous et al. [13]. No one developed DME during 
the follow-up period in the current study. In this study, 
while there was an absence of association with any type 
of fasting serum lipids and CMT changes, a significant 
correlation was observed between HbAlc and CMT 
changes during the observation period. This result 
showed that blood sugar level may be an essential 
determining factor for CMT. Altintas et al. [20] reported 
that the mean CMT of both eyes with NPDR was 297.12 
μm, as evaluated by SD-OCT. The CMT of each eye was 
not symmetrical in most of the patients, being 304.40 μm 
in the worse eye and 273.28 μm in the better eye. In the 
current study, l3 patients’ CMTs were asymmetrically 
changed in each eye of the same patient. This means that 
under different systemic conditions, while changing the 
HbA1c and fasting serum lipids level in the follow-up 
period in the same subjects, each retina could behave 
differently. Therefore, other local factors may influence 
each macula differently in the same subject. There is an 
upregulation of growth factors and cytokines, including 
angiopoietins, tumor necrosis factor, interleukins, and 
matrix metalloproteinases that contribute to the 
breakdown of the blood retinal barrier with consequent 
vascular leakage, finally being responsible for DME. 
Therefore, due to several variabilities in each patient, 
and even in each eye in the same patient, different 
responses to the same type of therapy could be 
indicated. To the best of the author’s knowledge, the 
current study was the first that revealed a significant 
correlation in changes of CMT and HbA1c, and even a 
slight alteration in HbA1c in eyes with treatment naive 
NPDR. Demonstration of asymmetric changes in CMT for 
both eyes of the same patient under changing systemic 
conditions is another important outcome of the current 
research. The limitation of this study was the short follow 
up period, and further studies are required to evaluate 
local factors that cause asymmetric involvement of each 
macula in the same patient. 
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